<div id="readability-page-1"><div id="parent_top_div">Dr Reddy's Laboratories on Saturday said it has launched its generic version of Semaglutide injection used in treatment of type 2 diabetes in Canada. The company is among the first firms to introduce a generic Semaglutide injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026, Dr Reddy's said in a statement. Canada is the first G7 country to grant market authorisation for Semaglutide injection, it added. &#34;The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development,&#34; Dr Reddy's CEO Erez Israeli said. He further said:&#34;With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients.&#34; The Canada launch builds on the momentum of the company's recent launch in India under the brand name Obeda, Israeli said. &#34;As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets,&#34; he noted. In Canada, Dr Reddy's Semaglutide injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, to improve glycemic control in combination with diet and exercise, the company said. It is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml. The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection, the statement said.</div></div>

如瑞迪博士

药明康德已在加拿大推出其用于 2 型糖尿病的仿制 Semaglutide 注射剂，成为在获得加拿大卫生部合规通知后首批推出该产品的公司之一。该注射剂提供 2 毫克和 4 毫克的预填充笔，设计为每周使用一次。首席执行官 Erez Israeli 强调了公司致力于提供高质量 GLP-1 疗法并扩大全球市场准入的承诺

如瑞迪博士实验室在加拿大推出了仿制的 Semaglutide 注射剂